Physician profile
Vikas Jain
NPI 1992965156
$673,349.85
in general payments reported to CMS, 2019-2025
23 companies · $173K in 2025
The $173K reported for 2025 was more than what 99% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $30K · 2021: $53K · 2022: $53K · 2023: $163K · 2024: $147K · 2025: $173K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $345K · Travel and Lodging: $52K · Consulting Fee: $51K · Honoraria: $17K · Food and Beverage: $17K · Education: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $345,154.45 |
| Travel and Lodging | $51,830.46 |
| Consulting Fee | $50,947.50 |
| Honoraria | $16,750.00 |
| Food and Beverage | $16,585.74 |
| Education | $528.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $435,832.93 | 2019-2025 | Xywav |
| Idorsia Pharmaceuticals US INC | $67,502.09 | 2022-2024 | Quviviq |
| Inspire Medical Systems, INC. | $49,027.56 | 2021-2025 | Inspire |
| Lilly USA, LLC | $45,117.02 | 2025 | Zepbound |
| Avadel Cns Pharmaceuticals, LLC | $44,536.97 | 2023-2025 | Lumryz |
| Harmony Biosciences LLC | $14,933.18 | 2020-2025 | Wakix |
| Axsome Therapeutics, INC. | $13,554.16 | 2023-2024 | Sunosi |
| Zoll Respicardia, INC. | $1,605.89 | 2022-2023 | Remede System |
| Novo Nordisk INC | $237.60 | 2019-2020 | |
| Eisai INC. | $198.91 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $195.23 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $124.98 | 2025 | Neffy |
| Fisher & Paykel Healthcare INC | $95.13 | 2025 | Fisher & Paykel Healthcare |
| Resmed Corp | $77.87 | 2021-2025 | |
| Glaxosmithkline, LLC. | $71.53 | 2025 | Shingrix, Arexvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $45.52 | 2021 | |
| Medtronic, INC. | $38.61 | 2023 | Linq II |
| Somnomed INC. | $33.69 | 2024 | |
| Abbott Laboratories | $31.50 | 2023 | Aveir |
| Ensodata, INC. | $26.96 | 2025 | |
| Arbor Pharmaceuticals, INC. | $24.83 | 2021 | |
| Vapotherm INC | $22.29 | 2021 | |
| Philips North America LLC | $15.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.